<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998123</url>
  </required_header>
  <id_info>
    <org_study_id>20-00698</org_study_id>
    <nct_id>NCT04998123</nct_id>
  </id_info>
  <brief_title>Efficacy of Intersectional Short Pulse Stimulation for Terminating Seizures</brief_title>
  <official_title>A Randomized, Sham-controlled Study of the Efficacy of Intersectional Short Pulse (ISP) Stimulation for Seizure Termination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study which seeks to develop a novel therapeutic approach, Intersectional Short&#xD;
      Pulse (ISP) stimulation for seizure termination. The device embodiment of ISP is a scalp EEG&#xD;
      recording system which also delivers spatially precise electrical stimulation in short pulses&#xD;
      to the targeted brain region. The study team has already collected safety and tolerability&#xD;
      data in human subjects, demonstrated ISP efficacy in terminating seizures in rodents, and&#xD;
      have tested the efficacy of this device to modulate normal human brain activity. Now this&#xD;
      study proposes to test the device's efficacy in stopping seizures in a within-subject&#xD;
      randomized, sham-controlled study design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The subject will be blinded to the treatment condition. The study team clinician will be aware of the treatment condition to provide to the clinical team any necessary information for clinical care. Decisions by expert review of EEG on seizure duration will be blinded to treatment condition as well.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean duration of seizures detected</measure>
    <time_frame>up to Day 10</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Seizures</condition>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ISP Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perpheral Stimulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeizureStop Device</intervention_name>
    <description>Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.</description>
    <arm_group_label>ISP Stimulation</arm_group_label>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Experiment 3: Epilepsy patients&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patients (age 18-65).&#xD;
&#xD;
          -  Fluent in English.&#xD;
&#xD;
          -  Epilepsy patients with poorly controlled (&gt;=2 seizures per week).&#xD;
&#xD;
          -  Focal onset seizures.&#xD;
&#xD;
          -  Seizure onset zone in the mesial temporal or neocortical onset as determined by &gt;2&#xD;
             concordant criteria, without discordant criteria (semiology, MRI Brain, and EEG).&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with skull defects.&#xD;
&#xD;
          -  Patients with implanted neurostimulator or other implanted cerebral hardware.&#xD;
&#xD;
          -  Patients with multifocal onset epilepsy.&#xD;
&#xD;
          -  Patients who are non-verbal or incapable of providing informed consent.&#xD;
&#xD;
          -  Current substance abuse.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Patients with non-MRI compatible implants (for Experiments 2 and 3).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anli Liu, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Borges Delfino de Souza</last_name>
    <email>Helen.Borges@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anli Liu, MD, MA</last_name>
    <email>Anli.Liu@nyulangone.org</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal will have access to the data upon reasonable request. Data are available for 5 years at a third party website (Link to be included).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

